OncoMatch/Clinical Trials/NCT06381830
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
Is NCT06381830 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies CAR-T Cell Therapy for lymphoma, b-cell.
Treatment: CAR-T Cell Therapy — The study is designed to evaluate the efficacy and safety of chimeric antigen receptor T-cell therapy following autologous stem cell transplantation for relapsed/refractory B-cell Non-Hodgkin's lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: car-t cell therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Lab requirements
Blood counts
platelet count≥45×10^9/l; hemoglobin≥8.0 g/dl; absolute neutrophil count≥1.0×10^9/l
Kidney function
ccr≥30 ml/min
Liver function
alt and ast≤3 times normal range
Cardiac function
lvef≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify